Treatment of in-stent restenosis with beraprost sodium: An experimental study of short-and intermediate-term effects in dogs

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 12, 2009, Pages 1164-1169

  Seiji, Kazumasa ^a   Tsuda, Masashi ^a   Matsuhashi, Toshio ^c   Takase, Kei ^a   Miyachi, Hideo ^a   Yamada, Takayuki ^a   Ishibashi, Tadashi ^b   Higano, Shuichi ^a   Takahashi, Shoki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Japan   (Japan)

Author keywords

Animal study; Antiproliferation; Beraprost sodium; Canine; Neointima formation; Restenosis; Smooth muscle cell proliferation; Stent

Indexed keywords

BERAPROST; CYCLINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DOG; DRUG EFFECT; EXPERIMENTAL STUDY; ILIAC VEIN; IMMUNOHISTOCHEMISTRY; IMPLANTATION; INTIMA; LONG TERM CARE; NONHUMAN; RESTENOSIS; SHORT COURSE THERAPY; SMOOTH MUSCLE FIBER; STENT; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE; Z STENT;

ANIMALS; BLOOD VESSEL PROSTHESIS; CELL PROLIFERATION; DOGS; EPOPROSTENOL; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; INFUSIONS, INTRAVENOUS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TIME FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 72149103320     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05209.x     Document Type: Article

References (33)

1. Sigwart U, Peul J, Mirkovith V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 1987 316 : 701 706.
2. Schillinger M, Sabeti S, Loewe C et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N. Engl. J. Med. 2006 354 : 1879 1888.
3. Ley EJ, Hood DB, Leke MA, Rao RK, Rowe VL, Weaver FA. Endovascular management of iliac vein occlusive disease. Ann. Vasc. Surg. 2004 18 : 228 233.
4. Hartung O, Otero A, Boufi M et al. Mid-term results of endovascular treatment for symptomatic chronic nonmalignant iliocaval venous occlusive disease. J. Vasc. Surg. 2005 42 : 1138 1144.
5. Serruys PW, Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 1994 331 : 489 495.
6. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 1994 331 : 496 501.
7. Rahel BM, Suttorp MJ, Laarman GJ et al. Primary stenting of occluded native coronary arteries: Final results of the primary stenting of occluded native coronary arteries (PRISON) study. Am. Heart J 2004 147 : e16 20.
8. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J. Endovasc. Ther. 2005 12 : 6 12.
9. Ihnat DM, Duong ST, Taylor ZC et al. Contemporary outcomes after superficial femoral artery angioplasty and stenting: The influence of TASC classification and runoff score. J. Vasc. Surg. 2008 47 : 967 974.
10. Holmes DR, Leon MB, Moses JW et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004 109 : 634 640.
11. King SB, Smith SC, Hirshfeld JW et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008 117 : 261 295.
12. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischamic stroke or transient ischaemic attack in high-risk patients (MATCH): Randamised, double-blaind, placebo-controlled trial. Lancet 2004 364 : 331 337.
13. Duda SH, Pusich B, Richter G et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-months results. Circulation 2002 106 : 1505 1509.
14. Nishio S, Matsuura H, Kanai N, Fukatsu Y et al. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn. J. Pharmacol. 1988 47 : 1 10.
15. Koh E, Morimoto S, Jiang B et al. Effect of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery 1993 20 : 242 252.
16. Shirotani M, Yui Y, Hattori R et al. U-61431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins 1991 41 : 97 110.
17. 2 in cultured rabbit aortic smooth muscle cells. Atherosclerosis 1988 71 : 165 171. (Pubitemid 18133736)
18. 2 analogue) in the atherosclerotic rabbit artery after angioplasty. J. Cardiovasc. Pharmacol. 1995 25 : 947 52.
19. Palmaz JC. Intravascular stents: Tissue-stent interactions and design considerations. AJR Am. J. Roentgenol. 1993 160 : 613 618.
20. Saito Y, Shimoyama M, Masuyama Y, Sakurai Y, Iizumi Y, Takenaka T. Effect of beraprost on neointimal thickening in the rabbit carotid artery caused by balloon catheter injury. Gendai-Iryo 1992 24 : 148 152 (in Japanese).
21. Matsuo T, Ohki Y. Classification of platelet aggregation patterns with two ADP solusions (the double-ADP method) and its clinical application to diabetes mellitus. Thromb. Res. 1977 11 : 453 461. (Pubitemid 8340418)
22. Nony P, Ffrench P, Girard P et al. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: A study in healthy male subjects. Can. J. Physiol. Pharmacol. 1996 74 : 887 893.
23. Serruys P, De Jaegere P, Bertrand M et al. Morphologic change in coronary artery stenosis with the Medtronic Wiktor stent: Initial results from the core laboratory for quantitative angiography. Cathet. Cardiovasc. Diagn. 1991 24 : 237 245.
24. Haude M, Erbel R, Issa H, Meyer J. Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz-Schatz stents. J. Am. Coll. Cardiol. 1993 21 : 26 34.
25. Ueda Y, Nanto S, Komamura K, Kodama K. Elastic recoil and intimal thickening after coronary stenting. J. Interv. Cardiol. 1995 8 : 137 141.
26. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents: Quantitative angiographic assessment. J. Am. Coll. Cardiol. 1993 21 : 1166 1174.
27. 2 analogue. Jpn. J. Pharmacol. 1987 43 : 81 90.
28. 2 derivatives and their inhibitory activities to human platelet aggregation. Adv. Prostaglandin Thromboxane Leukot. Res. 1987 15 : 279 281.
29. Hanke H, Kamenz J, Hassenstein S et al. Prolonged proliferative response of smooth muscle cells after experimental intravascular stenting. Eur. Heart J. 1995 16 : 785 793.
30. Matsuhashi T, Miyachi H, Ishibashi T, Sakamoto K, Yamadera A. In vivo evaluation of a fluorine-acryl-stylene-urethane-silicone antithrombogenic coating material copolymer for intravascular stents. Acad. Radiol. 1996 3 : 581 588.
31. Carter AJ, Laird JR, Frab A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J. Am. Coll. Cardiol. 1994 24 : 1398 1405.
32. Hanke H, Strohschneider T, Oberhoff M, Betz E, Karsch KR. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ. Res. 1990 67 : 651 659.
33. Strauss BH, Umans VA, van Suylen RJ et al. Directional atherectomy for treatment of restenosis within coronary stents: Clinical, angiographic and histologic results. J. Am. Coll. Cardiol. 1992 20 : 1465 1473.